^
Association details:
| Biomarker: | FGFR2 mutation |
|---|---|
| Cancer: | Solid Tumor |
| Drug: | tinengotinib (TT-00420) (Multi-tyrosine kinase inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Study to Evaluate the Efficacy and Safety of TT-00420 (Tinengotinib) in Cholangiocarcinoma
Excerpt:
...- Cohort B: other FGFR alterations, including FGFR2 mutations and FGFR1/3 alterations, including fusions...
Trial ID:
Source:
Title:
670P - Preliminary efficacy and safety of tinengotinib (TT-00420) monotherapy in Chinese patients (pts) with advanced solid tumors: Results from a phase Ib/II study
Published date:
10/16/2023
Excerpt:
Among 22 efficacy-evaluable pts, the median Progression-free survival (PFS) have reached 6.70 (95% CI, 3.22-NA) months. For 19 pts with measurable target lesions, the overall response rate (ORR) and disease control rate (DCR) were 15.8% and 89.5%, respectively. For 4 CCA pts harboring FGFR2 alteration, ORR was 50%, DCR was 100%....Tinengotinib monotherapy was well-tolerated in Chinese pts and 10 mg QD was selected as RP2D. Promising efficacy has been observed, especially in CCA with FGFR2 alteration.
Trial ID:
